There are few reports about the occurrence of hepatic VOD after BMT for severe aplastic anemia (SAA). We prospectively studied 17 patients with SAA after allogeneic BMT for the occurrence and severity of VOD. Plasma levels of protein C, protein S, antithrombin III, vWF, t-PA and PAI-1 were determined before preparative chemotherapy, on the day of marrow infusion, and on days 7, 14 and 21. VOD occurred in seven patients (41.2%) at a median of day 1 (range, day −2 to 15). Five had mild, and two moderate VOD. Platelet transfusion requirements were higher in the patients with VOD. The plasma levels of natural anticoagulants such as protein C, free protein S and antithrombin III decreased significantly on day 0 from the baseline levels. Plasma levels of t-PA, PAI-1 and vWF increased significantly in the early post-transplant period compared to the baseline levels. The mean plasma levels of t-PA on day 7 (P = 0.016) and PAI-1 on days 0 and 7 (P = 0.016, 0.032) were higher in the patients with VOD. In summary, we observed hypercoagulability and a high incidence of VOD after allogeneic BMT for SAA. Levels of t-PA and PAI-1 were significantly higher in the patients with VOD after BMT. Bone Marrow Transplantation (2000) 26, 657-662.
Veno-occlusive disease (VOD) of the liver is a major cause of morbidity and mortality after allogeneic bone marrow transplantation (BMT), and cytoreductive agents are the usual cause.
1 VOD has been reported with virtually every regimen used to prepare patients for BMT, and lower-dose cytoreductive therapy is associated with a lower incidence of hepatic toxicity. [2] [3] [4] In severe aplastic anemia (SAA), conditioning therapy usually consists of less intensive regimens such as cyclophosphamide alone or in combination with other immunosuppressive measures such as antithymocyte globulin (ATG) or nodal irradiation, and there are few reports about the occurrence of VOD after BMT for SAA. 4, 5 Cyclophosphamide is known to be toxic to hepatic sinus- oidal endothelial cells 6 and there have been several clinical reports of hepatotoxicity after cyclophosphamide. [7] [8] [9] Acrolein, which is a metabolite formed simultaneously with phosphoramide mustard through the initial oxidation of cyclophosphamide, may contribute to hepatotoxicity via mechanisms dependent on glutathione. 6, 10 Many transplantation conditioning regimens with a high incidence of fatal VOD include cyclophosphamide, which is also common to most conditioning regimens in BMT for SAA. 2 We prospectively studied the occurrence of VOD after BMT in patients with SAA who were conditioned with cyclophosphamide and ATG. We also serially measured the levels of various hemostatic markers, and correlated the changes of hemostatic markers with the development of hepatic VOD after BMT.
Patients and methods

Patients
All patients who underwent allogeneic BMT for SAA in the Asan Medical Center from April 1995 to November 1999 were enrolled into the study. Preparative therapy was cyclophosphamide (200 mg/kg) plus ATG (90 mg/kg) in all patients except one who had had an anaphylactic reaction to ATG prior to BMT and who received fludarabine 90 mg/m 2 in place of ATG. All patients were nursed in laminar air flow rooms. All had a triple lumen central venous catheter (CVC) placed. Vancomycin was given just prior to CVC placement and every 12 h for three more doses. Ciprofloxacin and acyclovir were administered for gut decontamination and viral prophylaxis, respectively. Hyperhydration and mesna were given for the prevention of cyclophosphamide-induced hemorrhagic cystitis. All blood products were leukocyte-depleted by filtration and irradiated prior to transfusion. Intravenous immunoglobulin 500 mg/kg was administered on day −7, then every other week. All patients received prophylactic therapy with cyclosporine and methotrexate for graft-versus-host disease (GVHD). Cyclosporine 1.5 mg/kg was given intravenously every 12 h starting on day −1. Intravenous methotrexate was given at a dose of 15 mg/m 2 on day 1 and 10 mg/m 2 on days 3, 6 and 11. No measure was performed for the prevention of VOD. On day 0, marrow from the donor was infused over 3-4 h. Recombinant human granulocyte colony-stimulating factor (rhG-CSF) 300 or 450 g was given intravenously once daily starting at day 0 to day 5. Total parenteral nutrition was given if indicated.
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Diagnosis of hepatic VOD
All patients were monitored prospectively for the occurrence of VOD. A diagnosis of VOD was made according to clinical criteria 2 as having two of the following before day 20 post transplant: (1) hyperbilirubinemia (bilirubin у2.0 mg/dl or 34.2 mol/l), (2) painful hepatomegaly, and (3) unexplained weight gain (Ͼ2% from baseline). No other explanation for these signs and symptoms could be present at the time of diagnosis. Severity of VOD was classified into mild, moderate, or severe. 2 In brief, patients who met the criteria of VOD, but who were not treated and whose illness was self-limited, were considered to have mild VOD. Those whose VOD resolved but who received treatment such as diuretics for fluid retention or narcotic analgesics for painful hepatomegaly, were considered to have moderate VOD. Patients who died of VOD or whose VOD did not resolve by 100 days post transplant were considered to have severe VOD. The onset of VOD was defined as the day on which the total serum bilirubin exceeded 2.0 mg/dl (34.2 mol/l) or the body weight increased more than 2% above baseline.
Assays of hemostatic parameters
Changes in protein C, protein S (total and free), antithrombin III (AT III), and von Willebrand factor antigen (vWF) were monitored in 15 patients from October 1995. Plasma levels of tissue plasminogen activator antigen (t-PA) and plasminogen activator inhibitor-1 antigen (PAI-1) were monitored in nine patients from May 1997. Each hemostatic parameter was determined before preparative chemotherapy, on the day of marrow infusion (day 0), and on days 7, 14 and 21. Protein C was measured by a commercially available enzyme-linked immunosorbent assay (ELISA) using monoclonal antibodies (Asserachrom-Protein C; Stago, Asniëres, France). Protein S (total and free), and vWF were also determined by a commercially available ELISA using monoclonal antibodies (Asserachrom-Total Protein S, Asserachrom-Free Protein S, Asserachrom-vWF; Stago). AT III was measured by chromogenic assay (Stachrome-AT III; Stago). The plasma levels of t-PA and PAI-1 were determined by ELISA method (TintElize tPA, TintElize PAI-1; Biopool, Umea, Sweden).
Statistical analysis
Individual characteristics were analyzed using the chisquare test for an association with development of VOD. Changes of each hemostatic parameter from the baseline values were analyzed using the Wilcoxon signed ranks test. The Mann-Whitney U test was used to analyze the differences in the values of each hemostatic parameter at different times between the patients who developed VOD and those who did not. The probability of engraftment was calculated using the Kaplan-Meier method and compared by log-rank analysis.
Results
Patient characteristics
Seventeen patients, 12 males and five females, were enrolled in the study. The median patient age was 29 years (range, 15-39). Sixteen patients had idiopathic and one hepatitis-associated aplastic anemia. Eight patients had high-risk features as they had been heavily transfused (more than 50 units) before BMT. Fifteen patients received allogeneic marrow grafts from HLA-identical siblings, one patient from an HLA phenotypically identical unrelated donor, and one from an HLA phenotypically one-locus mismatched unrelated donor.
Of the 17 patients enrolled, seven developed VOD (41.2%). Table 1 illustrates the patient characteristics which were putative risk factors for the development of VOD. Three patients had a history of previous liver disease; one had biopsy-proven hemochromatosis, and the other two had a history of acute viral hepatitis. The results of serologic tests for hepatitis B antigen and hepatitis C antibody were negative in all patients included in this study. On univariate analysis, the presence of infection within a week prior to BMT was the only risk factor for the occurrence of VOD (P = 0.023).
Clinical features of the patients with VOD
Among seven patients with VOD, five (71.4%) had mild and two (28.6 %) had moderate VOD (Table 2) . Four patients (57.1%) satisfied all three clinical criteria for VOD. The frequencies of clinical features associated with VOD were as follows: unexplained weight gain and hyperbilirubinemia both present in all cases (100.0%), tender hepatomegaly in four (57.1%), ascites and pulmonary infiltrate each in two (28.6%), and pleural effusion and peripheral edema in one each (14.3%). The median onset of VOD was day 1 (range, day −2 to day 15). The median value of maximum bilirubin levels was 6.9 mg/dl (range, 4.2-21.0 mg/dl) and the median % increase of body weight was 5.2% (range, 2.8-29.0%). The median duration of VOD was 22 days (range, 17-49 days). No patient received any specific therapy such as heparin or tissue plasminogen activator. Five patients with mild VOD recovered without any treatment, and two with moderate VOD required diuretics and pain control with intravenous morphine. The development of VOD did not affect neutrophil engraftment but platelet and reticulocyte engraftment showed a slower trend in the patients with VOD (Table 3 ). The patients who developed VOD required a larger amount of platelet transfusion (P = 0.032). Two patients, one with VOD and another without VOD, died of secondary engraftment failure.
Changes of hemostatic parameters
When the Wilcoxon signed rank test was performed on all patients, there were significant changes in hemostatic parameters following BMT (Table 4) . When compared with the baseline, significant decreases in mean plasma levels of natural anticoagulants were observed. Protein C level decreased significantly from the baseline on day 0. Total protein S level did not change significantly following BMT, but free protein S level decreased significantly from the baseline on days 0 and 21. The mean plasma level of AT III on day 0 fell significantly when compared to the baseline level. The mean plasma level of vWF increased significantly from the baseline on days 7, 14 and 21. The mean plasma levels of t-PA and PAI-1 also increased significantly from the baseline on day 14 and on day 0, respectively. The mean plasma levels of natural anticoagulants and vWF showed no significant differences at five different time points between patients with and without subsequent VOD, except for the baseline level of total protein S ( Table  4 ). The levels of t-PA and PAI-1 were not significantly Bone Marrow Transplantation different at the baseline between patients with and without subsequent VOD. The mean plasma level of t-PA was significantly higher in the patients with VOD on day 7 (P = 0.016), and the mean plasma level of PAI-1 was significantly higher in the patients with VOD when compared to the patients without VOD on day 0 (P = 0.016) and on day 7 (P = 0.032).
Discussion
Up to 54% of patients undergoing BMT are reported to develop VOD. 1 There is a marked disparity in both the incidence and severity of VOD in published reports of large- 
Table 3
Engraftment data and transfusion requirements of the patients according to the occurrence of VOD
Clinical outcomes Patients with VOD Patients without VOD P value (n = 7)
(n = 10) scale studies. This disparity reflects the inherent variable toxicities of different regimens, patient selection and diverse diagnostic criteria. 11 In general, VOD is known to be more common after BMT carried out for leukemia and lymphoma than after BMT for SAA. 12 There have been few studies of VOD after BMT in patients with SAA, except for case reports. 13, 14 VOD is caused by combinations of chemotherapy drugs, or chemotherapy drugs plus irradiation, and endothelial damage induced by high-dose chemoradiation therapy is believed to be the key event in the pathogenesis of VOD. 15 Although conditioning therapy of lower intensity is usually given to patients with SAA, cyclophosphamide, which is commonly included in preparative regimens for SAA, is known to be inherently hepatotoxic and can cause hepatic endothelial damage resulting in VOD. A substantial interpatient variability in 4-hydroxycyclophosphamide exposure at a given cyclophosphamide dose, as well as a correlation between exposure rates to metabolites of cyclophosphamide and the occurrence of VOD were reported. 16 In our study, we found a 41.2% of incidence of VOD in the patients with SAA transplanted after preparation with cyclophosphamide plus ATG. To our knowledge, this is the first prospective clinical study on the occurrence of VOD after BMT for SAA. In a retrospective study, VOD occurred in four among 24 patients who were transplanted for Fanconi anemia, and three of them had severe VOD. 5 In another study of 17 patients transplanted for hepatitisassociated SAA, VOD occurred in only one who died of VOD. 4 The diagnosis of VOD usually depends on clinical criteria because of a high frequency of false negative liver biopsy results 15 and a risk of bleeding from a percutaneous liver biopsy in thrombocytopenic patients. Clinical criteria for a diagnosis of VOD have been developed by both the Seattle and Baltimore groups. 1 The sensitivities and specificities for both criteria are greater than 88%. 17 In our ser-661 Table 4 The plasma levels of hemostatic parameters at five different times in all patients and in the patients with or without VOD ies, we monitored the signs of VOD prospectively and all the patients with VOD satisfied the clinical criteria which were developed by the Seattle group. Our study showed a somewhat higher incidence of VOD than have other reports. This may be due to the fact that we have prospectively observed the development of VOD with strict application of clinical criteria. Retrospective analysis may underestimate the incidence of VOD because mild cases can be easily overlooked. In this study, five of seven cases of VOD were mild and two were moderate. None had severe VOD. This finding is somewhat different from other report in which about 30% of the cases with VOD were severe. 2 The severity of VOD varies with the intensity of cytoreductive therapy used. 1 Patients who are given less intensive cytoreductive therapy are less likely to develop severe VOD. 2 All our patients received cyclophosphamide plus anti-thymocyte globulin Bone Marrow Transplantation which is less intensive compared to the preparative regimens used in bone marrow transplantation for leukemia. This may be the reason why most cases in our series were mild. All of our patients with VOD recovered spontaneously without specific therapy. Our patients had earlier onset of hyperbilirubinemia than in other reports. According to the Seattle data, mean day of onset of weight gain Ͼ2% of baseline weight was 0.7 Ϯ 4.3, and that of serum bilirubin Ͼ2 mg/dl was 5.9 Ϯ 4.8. 1 The median day of onset of weight gain was 5 (range, −1 to 17) and that of jaundice, 1 (range, −2 to 15) in our series. Platelet transfusion requirements were higher in the patients with VOD than in the patients without VOD, and this finding is consistent with previous studies. 2, 18 A number of investigators have evaluated various hemostatic parameters associated with VOD and uncomplicated BMT. A state of hypercoagulability was demonstrated in association with a decrease of natural anticoagulants (protein C, protein S and AT III), 19, 20 an increase of procoagulants (factor VIII, fibrinogen and vWF antigen), 21, 22 or changes in fibrinolytic parameters (t-PA and PAI-1). 23 In our study, the patients with SAA also experienced a hypercoagulable state in the early post-transplant period. Plasma levels of natural anticoagulants protein C, free protein S and AT III decreased significantly on day 0 from baseline levels, and the plasma levels of t-PA and PAI-1 as well as vWF increased significantly in the early post-transplant period compared to baseline levels. These early posttransplant changes of hemostatic parameters may potentially create hypercoagulability, which appears to be linked to the development of VOD. The relatively small changes in natural anticoagulants may reflect the finding that most patients had no, or mild VOD.
VOD
Although it is not certain whether changes in hemostatic parameters are involved in the pathogenesis of VOD or are epiphenomena of the disease process, these changes can be used as markers for VOD. In our previous study, we showed that plasma levels of protein C and AT III were significantly lower in patients with moderate to severe VOD when compared to patients with no/mild VOD on day 7 and thereafter. 24 PAI-1 has also been reported to identify VOD in patients who have undergone BMT in several studies. 23, 25 In this study, the plasma levels of natural anticoagulants were not significantly different between patients with VOD and patients without VOD. This may be because the majority of patients with VOD were mild cases. 24 The levels of t-PA and PAI-1 were significantly higher on days 0 and 7 in the patients with VOD compared to those without. This finding suggests that t-PA and PAI-1 may be more sensitive than natural anticoagulants in the prediction of the occurrence of VOD, especially the milder forms.
In summary, we observed a high incidence of VOD as well as a hypercoagulable state in the patients with SAA who underwent allogeneic BMT after preparation with cyclophosphamide and ATG. Early increase in plasma levels of t-PA and PAI-1 may be a predictive marker for the occurrence of VOD after BMT for SAA.
